TORONTO, Aug. 24 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) today announced, at the request of Market Surveillance, on behalf of the Canadian National Stock Exchange, that the company is not aware of any adverse material events to report that would account for the recent trading activity in its stock.
About Biosign Technologies Inc.
Biosign Technologies Inc. (CNSX: BIO) provides biomedical and intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose and medication. The core technology combines measurement, analysis and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.
The CNSX has neither approved nor disapproved the contents of this press release.
SOURCE Biosign Technologies Inc.
For further information: For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: email@example.com